Dr. Sanjay Popat, Debating With Us Where the Dust Has Settled with Adjuvant Osimertinib After the ADAURA Trial | BTJ-003 Published November 29, 2020 at 1500 × 1500 in Dr. Sanjay Popat, Debating With Us Where the Dust Has Settled with Adjuvant Osimertinib After the ADAURA Trial | BTJ-003 Co-hosts Charu Aggarwal and Jack West are joined by guest expert Sanjay Popat to discuss how practice should change & open questions on molecular testing & adjuvant EGFR inhibitor osimertinib for resected early stage EGFR mutation-positive NSCLC.
